中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 4
Apr.  2017

Clinical features of patients developing primary hepatocellular carcinoma during anti-HBV therapy with nucleos (t) ide analogues

DOI: 10.3969/j.issn.1001-5256.2017.04.016
  • Published Date: 2017-04-20
  • Objective To investigate the clinical features of patients developing hepatocellular carcinoma ( HCC) during anti-hepatitis B virus ( HBV) therapy with nucleos ( t) ide analogues ( NAs) . Methods A total of 542 patients who were diagnosed with HCC for the first time in The Third Affiliated Hospital of Sun Yat-Sen University from January 2008 to September 2014 were enrolled, and they all had chronic HBV infection. According to the presence or absence of standard therapy with NAs, they were divided into antiviral group ( 130 patients) and non-antiviral group ( 412 patients) . A retrospective analysis was performed for their clinical data, including age, sex, family history of tumor, duration of HBV infection, the time when a confirmed diagnosis of liver cirrhosis was made, history of drinking, history of diabetes, history of medication, laboratory parameters, liver pathology, and imaging findings, and these data were compared between the two groups.The t-test was used for comparison of normally distributed continuous data between groups, the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups, and the chi-square test was used for comparison of categorical data between groups. Results Compared with the non-antiviral group, the antiviral group had significant increases in the proportion of patients with liver cirrhosis ( 90. 0% vs 78. 4%, χ2= 8. 528, P = 0. 003) and HBe Ag-positive rate ( 29. 4% vs 18. 5%, χ2= 6. 794, P = 0. 009) .There was a significant difference in the constitution of HBV DNA between the two groups ( χ2= 173. 142, P < 0. 001) , as well as significant differences in alanine aminotransferase, gamma-glutamyl transpeptidase, and alpha-fetoprotein ( all P < 0. 001) . Compared with the non-antiviral group, the antiviral group had a higher proportion of patients with early-or intermediate-stage liver cancer, smaller and fewer cancer lesions, and a lower proportion of patients with vascular invasion or distant metastasis ( all P < 0. 001) . Among the patients in the antiviral group, 80% ( 104/130) developed HCC within 5 years of anti-HBV therapy. Conclusion Some patients with chronic HBV infection who receive long-term NAs as the anti-HBV therapy still develop HCC, especially those with liver cirrhosis, and most of these cases occur within 5 years of anti-HBV therapy. Most patients treated with NAs are diagnosed at the early stage of HCC, suggesting that standard follow-up is of vital importance.

     

  • [1]HALEGOUA-DE MARZIO D, HANN HW.Then and now:the progress in hepatitis B treatment over the past 20 years[J].World J Gastroenterol, 2014, 20 (2) :401-413.
    [2]YE XQ, GAO FY, SUN L, et al.Improvement of improve the two years survival rate of patients with hepatitis B virus-related primary liver cancer after antiviral treatment[J/CD].Chin J Exp Clin Infect Dis:Electronic Edition, 2016, 10 (3) :304-310. (in Chinese) 叶协琼, 高方媛, 孙乐, 等.抗病毒治疗提高乙型肝炎病毒相关原发性肝癌患者两年生存率[J/CD].中华实验和临床感染病杂志电子版, 2016, 10 (3) :304-310.
    [3]LIN CL, KAO JH.Risk stratification for hepatitis B virus related hepatocellular carcinoma[J].J Gastroenterol Hepatol, 2013, 28 (1) :10-17.
    [4] BRUIX J, SHERMAN M.Management of hepatocellular carcinoma:an update[J].Hepatology, 2011, 53 (3) :1020-1022.
    [5]YANG HI, YUEN MF, CHAN HL, et al.Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B) :development and validation of a predictive score[J].Lancet Oncol, 2011, 12 (6) :568-574.
    [6]European Association ror the Study of the Liver.EASL clinical practice guidelines:management of chronic hepatitis B virus infection[J].J Hepatol, 2012, 57 (1) :167-185.
    [7]WONG GL, WONG VW, CHAN HL.Combination therapy of interferon and nucleotide/nucleoside analogues for chronic hepatitis B[J].J Viral Hepat, 2014, 21 (12) :825-834.
    [8] WATANABE T, TOKUMOTO Y, JOKO K, et al.Effects of longterm entecavir treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients[J].Hepatol Int, 2016, 10 (2) :320-327.
    [9]SINGAL AK, SALAMEH H, KUO YF, et al.Meta-analysis:the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B[J].Aliment Pharmacol Ther, 2013, 38 (2) :98-106.
    [10]HOSAKA T, SUZUKI F, KOBAYASHI M, et al.Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection[J].Hepatology, 2012, 58 (1) :98-107.
    [11]LIAW YF, SHEEN IS, LEE CM, et al.Tenofovir disoproxil fumarate (TDF) , emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease[J].Hepatology, 2011, 53 (1) :62-72.
    [12] PAPATHEODORIDIS GV, MANOLAKOPOULOS S, TOULOUMI G, et al.Virological suppression does not prevent the development of hepatocellular carcinoma in HBe Ag-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral (s) starting with lamivudine monotherapy:results of the nationwide HEPNET.Greece cohort study[J].Gut, 2011, 60 (8) :1109-1116.
    [13] SINGAL AK, SALAMEH H, KUO YF, et al.Meta-analysis:the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B[J].Aliment Pharmacol Ther, 2013, 38 (2) :98-106.
    [14]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.
    [15]Ministry of Health of the People's Republic of China.Diagnosis, management, and treatmen of hepatocellular carcinoma (V2011) [J].J Clin Hepatol, 2011, 27 (11) :1141-1159. (in Chinese) 中华人民共和国卫生部.原发性肝癌诊疗规范 (2011年版) [J].临床肝胆病杂志, 2011, 27 (11) :1141-1159.
    [16]Biliary Tract Group, Chinese Society of Surgery, Chinese Medical Association Guidelines for the diagnosis and treatment of hepatolithiasis[J].Chin J Intect Dis, 2001, 40 (1) :56-62. (in Chinese) 中华医学会传染病与寄生虫病学分会, 肝病学分会.病毒性肝炎防治方案[J].中华传染病杂志, 2001, 40 (1) :56-62.
    [17] SHEN YC, HSU C, CHENG CC, et al.A critical evaluation of the preventive effect of antiviral therapy on the development of hepatocellular carcinoma in patients with chronic hepatitis C or B:a novel approach by using meta-regression[J].Oncology, 2012, 82 (5) :275-289.
  • Relative Articles

    [1]Ke SHI, Qun ZHANG, Xianbo WANG, Ying FENG. Effect of intestinal flora and metabolites on the development and progression of acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2025, 41(3): 568-573. doi: 10.12449/JCH250327
    [2]Viral Hepatitis Group of Professional Committee of Liver Disease (combined traditional Chinese and western medicine) of Chinese Research Hospital Association, Zhejiang Provincial Key Laboratory for Accurate Diagnosis and Treatment of Chronic Liver Diseases. Guidelines for fecal microbiota transplantation therapy in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2025, 41(3): 424-431. doi: 10.12449/JCH250306
    [3]Xiaoming WU, Qiang HE, Linyi HOU, Yan HU, Xiaofang ZHEN, Jing HAO, Yan SHENG. Effect of Yudantong decoction on intestinal flora and intestinal barrier function in mice with cholestasis induced by α-naphthyl isothiocyanate[J]. Journal of Clinical Hepatology, 2023, 39(4): 864-875. doi: 10.3969/j.issn.1001-5256.2023.04.018
    [4]Hongkai XU, Chunfu WANG, Ye ZHANG, Jianqi LIAN. Role of fecal microbiota transplantation in chronic liver diseases[J]. Journal of Clinical Hepatology, 2023, 39(9): 2237-2243. doi: 10.3969/j.issn.1001-5256.2023.09.031
    [5]Guirong CHEN, Minggang WANG, Huaming LIN, Huiping YAN, Xiufeng WANG. Changes and pathogenic mechanism of intestinal flora in acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2023, 39(8): 1992-1998. doi: 10.3969/j.issn.1001-5256.2023.08.034
    [6]Quan ZHOU, Chunlin CAI, Jinqiang LI. Gut-liver axis: Intestinal microbial homeostasis and hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(11): 2710-2717. doi: 10.3969/j.issn.1001-5256.2023.11.029
    [7]Yixin HOU, Qun ZHANG, Yuyong JIANG, Hao YU, Yuying YANG, Xianbo WANG. Effect of Liangxue Jiedu decoction on intestinal flora in patients with hepatitis B virus-related acute-on-chronic liver failure: An analysis based on high-throughput sequencing[J]. Journal of Clinical Hepatology, 2022, 38(6): 1280-1287. doi: 10.3969/j.issn.1001-5256.2022.06.013
    [8]Fuchun WANG, Ziyi LI, Wanjie ZHANG, Xiaorong MAO, Junfeng LI. The significance of gut microbiota in acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2022, 38(7): 1667-1670. doi: 10.3969/j.issn.1001-5256.2022.07.040
    [9]Transplantation Immunology Committee of Branch of Organ Transplantation Physician of Chinese Medical Doctor Association, Organ Transplant Rehabilitation Committee of China Association Rehabilitation Medicine, Branch of Organ Transplantation Physician of Guangdong Medical Doctor Association. Expert consensus on liver transplantation perioperative evaluation and rehabilitation for acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2022, 38(12): 2701-2708. doi: 10.3969/j.issn.1001-5256.2022.12.005
    [10]Hui DENG, Bin ZHANG, Bin ZHU, Zhayier DILIHUMAER, Weixian WANG, Chunxia GUO, Dongliang YANG, Xin ZHENG, Junzhong WANG, Baoju WANG. Research advances in the role of gut microbiota in chronic hepatitis B, chronic hepatitis C, and related liver diseases[J]. Journal of Clinical Hepatology, 2022, 38(5): 1143-1147. doi: 10.3969/j.issn.1001-5256.2022.05.035
    [11]Mingyin MAN, Nana LI, Yue BU, Kaijiang YU. Influence of mitochondria-targeted antioxidant SS-31 on acute liver injury in a mouse model of sepsis[J]. Journal of Clinical Hepatology, 2022, 38(2): 392-396. doi: 10.3969/j.issn.1001-5256.2022.02.025
    [12]Xujuan LUO, Xue BAI, Zenghui LI, Fan LIU, Hao TANG, Ruoxin LI, Guodong YANG. Clinical effect of fecal microbiota transplantation versus the traditional Chinese medicine Rheum officinale in a rat model of hyperlipidemic acute pancreatitis[J]. Journal of Clinical Hepatology, 2022, 38(12): 2767-2773. doi: 10.3969/j.issn.1001-5256.2022.12.016
    [13]Ziwei GUO, Jiaxin ZHANG, Shuo LI, Xiaobin LI, Shun ZHU, Qian JIN, Xiaoke LI, Yongan YE. Research advances in intestinal flora and the development and prognosis of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2022, 38(5): 1137-1142. doi: 10.3969/j.issn.1001-5256.2022.05.034
    [14]Lingyan XIAO, Awen XING, Shanzhong TAN. Research advances in the association between liver failure and intestinal barrier injury[J]. Journal of Clinical Hepatology, 2021, 37(11): 2710-2714. doi: 10.3969/j.issn.1001-5256.2021.11.049
    [15]Yanyan CHEN, Yanmei LAN, Minggang WANG, Dewen. MAO. Mechanism of action of bile acid-farnesoid X receptor-intestinal microecological axis in the development of liver failure and liver regeneration[J]. Journal of Clinical Hepatology, 2021, 37(2): 480-484. doi: 10.3969/j.issn.1001-5256.2021.02.049
    [16]Menghao LI, Kai LI, Shihao TANG, Zhengyu WANG, Wengang GUO, Zhanxin YIN, Guohong HAN. Changes in gut microbiota after transjugular intrahepatic portosystemic shunt in cirrhotic patients with mild hepatic encephalopathy in different prognosis groups[J]. Journal of Clinical Hepatology, 2021, 37(2): 326-330. doi: 10.3969/j.issn.1001-5256.2021.02.016
    [17]Li HongShan, Hu YiYang. Gut microecology: An important target of traditional Chinese medicine in the treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(1): 14-18. doi: 10.3969/j.issn.1001-5256.2020.01.002
    [18]Huang YunYi, Liu Yao, Zhang Qun, Shi Ke, Wang XianBo. Association of intestinal microecology with hepatic encephalopathy[J]. Journal of Clinical Hepatology, 2020, 36(4): 912-914. doi: 10.3969/j.issn.1001-5256.2020.04.045
    [19]Huang Qian, Zhang HaiBo, Li JingTao, Wei HaiLiang, Yan ShuGuang, Hui Yi, Chang ZhanJie. Research advances in the mechanism of action of intestinal microecology in intrahepatic cholestasis[J]. Journal of Clinical Hepatology, 2019, 35(10): 2355-2359. doi: 10.3969/j.issn.1001-5256.2019.10.050
    [20]Zheng Wei, Zhang YongHong, Zhao Yan. Role of intestinal microflora in the pathogenesis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(7): 1613-1615. doi: 10.3969/j.issn.1001-5256.2019.07.041
  • Cited by

    Periodical cited type(9)

    1. 刘韦,白浪. 慢加急性肝衰竭动物模型研究现状. 临床肝胆病杂志. 2024(01): 187-192 . 本站查看
    2. 陈然,王帅,高扬,杨志琴,徐严. HBV相关慢加急性肝衰竭合并脓毒症的诊疗进展. 肝脏. 2024(07): 867-870 .
    3. 刘扬,洪文,黄克林,杨博,刘亚坡,路明. 粪菌移植对顽固性便秘小鼠的肠道菌群和肠道动力以及TLR4/NF-κB通路蛋白的影响. 现代生物医学进展. 2024(16): 3020-3024 .
    4. 于丹丹,刘亚坡,洪文,杨博,张媛. 粪菌移植对顽固性便秘患者肠道功能、免疫功能及炎症反应的改善效果. 结直肠肛门外科. 2024(05): 578-583 .
    5. 阮浩龙,王宁,于鸿浩,岳鹏鹏. 基于基因编辑技术研究特定基因对小鼠肠道微生物的影响. 中国医学工程. 2024(11): 44-49 .
    6. 徐洪凯,汪春付,张野,连建奇. 粪菌移植在慢性肝病治疗中的应用. 临床肝胆病杂志. 2023(09): 2237-2243 . 本站查看
    7. 周荃,蔡春琳,李金强. 肠-肝轴:肠道微生物稳态与肝细胞癌. 临床肝胆病杂志. 2023(11): 2710-2717 . 本站查看
    8. 周宜,刘晓琴,吴学敏,张浩,王海琴,王红亮,孟祥龙. 乳香及其炮制品对葡聚糖硫酸钠诱导小鼠炎症性肠病的保护作用. 现代药物与临床. 2022(07): 1432-1438 .
    9. 刘蕾,高越颖,郭琳,邱立朋,李会,耿燕. 酒精性肝损伤保护的药理实验教学设计. 实验室研究与探索. 2022(05): 238-243 .

    Other cited types(2)

  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 2.3 %FULLTEXT: 2.3 %META: 94.7 %META: 94.7 %PDF: 3.0 %PDF: 3.0 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 5.3 %其他: 5.3 %其他: 0.6 %其他: 0.6 %India: 0.2 %India: 0.2 %[]: 0.2 %[]: 0.2 %上海: 2.1 %上海: 2.1 %兰州: 0.2 %兰州: 0.2 %北京: 7.4 %北京: 7.4 %南宁: 0.6 %南宁: 0.6 %台州: 0.2 %台州: 0.2 %吉林: 0.8 %吉林: 0.8 %哥伦布: 0.2 %哥伦布: 0.2 %张家口: 1.7 %张家口: 1.7 %杭州: 0.8 %杭州: 0.8 %湖州: 0.4 %湖州: 0.4 %潍坊: 0.2 %潍坊: 0.2 %石家庄: 0.4 %石家庄: 0.4 %秦皇岛: 0.4 %秦皇岛: 0.4 %芒廷维尤: 39.4 %芒廷维尤: 39.4 %莫斯科: 1.9 %莫斯科: 1.9 %衡水: 0.2 %衡水: 0.2 %西宁: 33.7 %西宁: 33.7 %西安: 0.2 %西安: 0.2 %郑州: 0.6 %郑州: 0.6 %重庆: 0.2 %重庆: 0.2 %长春: 1.3 %长春: 1.3 %长沙: 0.2 %长沙: 0.2 %长治: 0.2 %长治: 0.2 %其他其他India[]上海兰州北京南宁台州吉林哥伦布张家口杭州湖州潍坊石家庄秦皇岛芒廷维尤莫斯科衡水西宁西安郑州重庆长春长沙长治

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (2602) PDF downloads(499) Cited by(11)
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return